Shruti Gupta, Ilya G Glezerman, Jamie S Hirsch, Kevin L Chen, Nishant Devaraj, Sophia L Wells, Robert H Seitter, Sarah A Kaunfer, Arunima M Jose, Shreya P Rao, Jessica L Ortega, Olivia Green-Lingren, Robert Hayden, Pavan K Bendapudi, Donald F Chute, Meghan E Sise, Kenar D Jhaveri, Valda D Page, Matthew H Abramson, Shveta S Motwani, Wenxin Xu, Kartik Sehgal, Kerry L Reynolds, Anip Bansal, Ala Abudayyeh, David E Leaf
OBJECTIVE: To develop and externally validate a prediction model for severe cisplatin associated acute kidney injury (CP-AKI). DESIGN: Multicenter cohort study. SETTING: Six geographically diverse major academic cancer centers across the US. PARTICIPANTS: Adults (≥18 years) receiving their first dose of intravenous cisplatin, 2006-22. MAIN OUTCOME MEASURES: The primary outcome was CP-AKI, defined as a twofold or greater increase in serum creatinine or kidney replacement therapy within 14 days of a first dose of intravenous cisplatin...
March 27, 2024: BMJ: British Medical Journal